SCHEMBL238314

SCHEMBL238314

Cc1cc2ncc3cc(-c4ccccc4)c(-c4ccc(NC(=O)N5CCOCC5)cc4)nc3n2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
GAA P10253 3/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 2/20 0.43
HSD17B10 Q99714 1/20 0.43
ABL1 P00519 1/20 0.43
ALDH1A1 P00352 2/20 0.42
KDR P35968 1/20 0.42
MERTK Q12866 1/20 0.40
JAK1 P23458 1/20 0.40
GSK3B P49841 2/20 0.39
DYRK1A Q13627 2/20 0.39
AOC3 Q16853 2/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16986829 0.88 KDR (0.40) SMN1; SMN2GAAMAPTHPGDKDM4E
SCHEMBL237338 0.84 KDR (0.48) SMN1; SMN2GAAMAPTHPGDKDM4E
SCHEMBL2755250 0.83 AKT1 (0.51) GAAKDR
SCHEMBL235465 0.80 AKT1 (0.51) CYP2C19SMN1; SMN2MAPTNPSR1ALDH1A1
SCHEMBL238553 0.80 ACVR1 (0.45) SMN1; SMN2KDM4ENPC1ALDH1A1JAK1
SCHEMBL236154 0.78 ALDH1A1 (0.44) MAPTHPGDNPSR1KDM4EALDH1A1
SCHEMBL237127 0.76 AKT1 (0.61) ABL1GSK3BDYRK1AKMT2A
SCHEMBL235907 0.76 AKT1 (0.59) GSK3BDYRK1AKMT2A
SCHEMBL238251 0.76 AKT1 (0.47) SMN1; SMN2HPGDNPC1RAB9AMEN1
SCHEMBL237603 0.76 TNKS (0.40) SMN1; SMN2MAPTHPGDKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US claimed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 CYP2C9 3145/4885CYP2C19 3220/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.